Financial-condition grades for SEC filers
Company Report · as of Oct 9, 2026
|
| DiaMedica Therapeutics Inc.DMAC · healthcare | |
|---|---|
| Grade | Nonecomputable_factors_below_threshold: 4 of 14 inputs computable; 7 are required |
| Reliability | 0.83 AUCfailure model, filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| Peer failure rate | 1.07% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025 |
| Size band | $12.5M to $120M assetstotal assets $61.4M[1] |
| Standard universe | outsiderevenue above $1M and assets above $10M[1-2] |
| Warnings | dilution, short runway, thin datanot computable: distress, fortress balance sheet |
| Inputs computable | 4 of 14 |
| Graded from | filings received through Mar 30, 2026193 days before the rescan; every figure keyed to the SEC receipt date |
| Last close | $8.002026-10-08; market equity $431.4M; iex feed |
| Price used in grade | None |
| Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date. Open this report as it stood on | ||||||||||||||||||||
Each date opens the report as it stood on that rescan. |
Business, in the company's words. Opening of Item 1 of the 10-K received Mar 30, 2026; the document on sec.gov.
We are a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from severe ischemic disease with two main clinical programs focused on preeclampsia (PE) / fetal growth restriction (FGR) and acute ischemic stroke (AIS). Our lead candidate DM199 (rinvecalinase alfa), is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (rhKLK1) protein to be clinically studied in patients and has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of AIS.
7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.
Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.
| Input | Percentile, 0 to 100 | Value | Source | Peer median | Percentile | Peers | Period end |
|---|---|---|---|---|---|---|---|
| Profitability, sleeve percentile 54.3 | |||||||
| Gross profitability | not computable | 32.2% | |||||
| one or more required annual facts are missing | |||||||
| Return on invested capital | not computable | 9.3% | |||||
| one or more required annual facts are missing | |||||||
| Accruals ratio | (6.9%) | [1,6-8] | (6.6%) | 54.3 | 811 | 2025-12-31 | |
| Gross margin stability, five years | not computable | 2.8 pts | |||||
| five annual gross margins are required; found 0 | |||||||
| Solvency, sleeve percentile 12.8 | |||||||
| Twelve-month failure probability | not computable | 0.07% | |||||
| liabilities and a nearby cover-page share count are required at 2026-06-30 | |||||||
| Altman Z double-prime | not computable | (0.31) | |||||
| one or more required annual facts are missing | |||||||
| Net debt to EBITDA | not computable | 1.82x | |||||
| one or more required annual facts are missing | |||||||
| Interest coverage | not computable | (4.51x) | |||||
| one or more required annual facts are missing | |||||||
| Current ratio | 11.81x | [9-10] | 2.96x | 12.8 | 839 | 2025-12-31 | |
| Growth and financing, sleeve percentile 43.0 | |||||||
| Revenue growth, three-year compound | not computable | 10.0% | |||||
| four annual observations are required; found 1 | |||||||
| Free cash flow growth, three-year compound | not computable | 10.9% | |||||
| current FCF must be positive and base FCF must exceed $100,000 | |||||||
| Reinvestment rate | not computable | 37.1% | |||||
| pretax income must exceed the validity floor and imply a 0%-100% tax rate | |||||||
| Asset growth, three years | 21.3% | [1,8,11-12] | 2.1% | 20.3 | 704 | 2025-12-31 | |
| Net share issuance, one year | 25.7% | [3-4] | 2.5% | 65.6 | 634 | 2026-03-27 | |
Gross profitability. Revenue less cost of goods sold, over total assets.
Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.
Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.
Twelve-month failure probability. CHS model; lower is stronger.
Net debt to EBITDA. Lower is stronger.
Net share issuance, one year. Split-adjusted; lower is stronger.
Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.
| Measure | Value | Peer median | Percentile | Reading |
|---|---|---|---|---|
| Twelve-month price change, skipping the latest month | (7.6%) | 8.0% | 42 | hotter than 42 of 100 peers |
| Distance from 52-week high | (14.7%) | (31.4%) | 74 | closer to its high than 74 of 100 peers |
| EBIT to enterprise value | not computable | (1.5%) | required accounting or market input is missing | |
| Free cash flow yield | (6.7%) | (1.0%) | 38 | pricier than 62 of 100 peers |
| Book value to price | 0.09 | 0.28 | 25 | pricier than 75 of 100 peers |
| Sales to price | 0.00 | 0.31 | 3 | pricier than 97 of 100 peers |
| Composite equity issuance, five years | 105.5% | 20.3% | 78 | more equity-funded than 78 of 100 peers |
| Relative strength against the sector, log excess return | (0.29) | (0.14) | 42 | ahead of 42 of 100 peers |
Inputs: market equity $431.9M; EBIT -$34.4M; free cash flow -$29.1M; book equity $38.3M; sales $500,000; cash $5.1M[13].
Diagnostics do not feed the grade.
| Piotroski F-score: None of 9, period end 2025-12-31 | ||
|---|---|---|
| Return on assets above zero | (70.7%) | ✗ fail[6,8] |
| Operating cash flow above zero | -$29.1M | ✗ fail[7] |
| Return on assets improved | (25.6 pts) | ✗ fail[6,8,11,14] |
| Operating cash flow exceeds net income | $3.7M | ✓ pass[6-7] |
| Long-term leverage fell | n/a[1,8,11] | |
| Current ratio improved | 353.7 pts | ✓ pass[9-10,15-16] |
| No new shares issued | 25.7% | ✗ fail[3-4] |
| Gross margin improved | n/a | |
| Asset turnover improved | n/a[8,11] | |
|
Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.
| # | Concept | XBRL tag | Value | Period end | Received | Form | Links |
|---|---|---|---|---|---|---|---|
| 1 | assets | us-gaap:Assets | $61.4M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 2 | revenue | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax | $500,000 | 2018-12-31 | 2020-03-23 | 10-K | filing · viewer · series |
| 3 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 53,882,506 | 2026-03-27 | 2026-03-30 | 10-K | filing · viewer · series |
| 4 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 42,855,660 | 2025-03-14 | 2025-03-17 | 10-K | filing · viewer · series |
| 5 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $5.1M | 2026-06-30 | 2026-08-10 | 10-Q | filing · viewer · series |
| 6 | net income | us-gaap:NetIncomeLoss | -$32.8M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 7 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$29.1M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 8 | assets | us-gaap:Assets | $46.3M | 2024-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 9 | current assets | us-gaap:AssetsCurrent | $60.6M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 10 | current liabilities | us-gaap:LiabilitiesCurrent | $5.1M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 11 | assets | us-gaap:Assets | $54.2M | 2023-12-31 | 2025-03-17 | 10-K | filing · viewer · series |
| 12 | assets | us-gaap:Assets | $34.4M | 2022-12-31 | 2024-03-19 | 10-K | filing · viewer · series |
| 13 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 53,925,697 | 2026-08-03 | 2026-08-10 | 10-Q | filing · viewer · series |
| 14 | net income | us-gaap:NetIncomeLoss | -$24.4M | 2024-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 15 | current assets | us-gaap:AssetsCurrent | $44.6M | 2024-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 16 | current liabilities | us-gaap:LiabilitiesCurrent | $5.4M | 2024-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 17 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$17.2M | 2026-06-30 | 2026-08-10 | 10-Q | filing · viewer · series |
| 18 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$9.1M | 2026-03-31 | 2026-05-06 | 10-Q | filing · viewer · series |
| 19 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$21.3M | 2025-09-30 | 2025-11-12 | 10-Q | filing · viewer · series |
| 20 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$14.7M | 2025-06-30 | 2026-08-10 | 10-Q | filing · viewer · series |
Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.
Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.
Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.
Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.
Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.